基于2-[18F]FDG PET/CT的影像组学特征对免疫组化结果不确定的原发性乳腺癌HER2状态的预测价值
回顾性纳入154例免疫组化HER2结果不确定的原发性乳腺癌患者,评估2-[18F]FDG PET/CT影像组学特征预测HER2状态的能力。五种常规PET参数均无法区分HER2阳性与阴性队列(P=0.104-0.544),而影像组学模型在训练队列AUC为0.887(95%CI 0.824-0.950),验证队列为0.766(95%CI 0.616-0.916),外部测试队列为0.788(95%CI 0.633-0.944)。结论认为影像组学特征能无创预测HER2状态,能力与FISH检测相当。
要点
- 常规PET参数(SUVmax、SUVmean、SUVpeak、MTV、TLG)均无法区分HER2阳性与阴性(P=0.104-0.544)。
- 影像组学模型训练队列AUC 0.887(95%CI 0.824-0.950),验证队列0.766(95%CI 0.616-0.916)。
- 外部测试队列AUC 0.788(95%CI 0.633-0.944),与FISH检测能力相当。
核心结论
- 基于2-[18F]FDG PET/CT图像的影像组学特征能够无创预测HER2状态,其能力与FISH检测相当,尤其适用于免疫组化HER2结果不确定的患者。
研究设计与样本
- 回顾性研究,纳入154例免疫组化HER2结果不确定的原发性乳腺癌患者,提取2-[18F]FDG PET/CT影像组学特征并用LASSO算法建立影像组学模型,另纳入来自外部机构的37例乳腺癌患者进行外部验证。
诊断标准与关键数值
- 常规PET参数SUVmax、SUVmean、SUVpeak、MTV、TLG在HER2阳性与阴性队列间差异均无统计学意义(P=0.104-0.544)。
- 影像组学模型预测HER2状态的AUC在训练队列为0.887(95%CI 0.824-0.950),在验证队列为0.766(95%CI 0.616-0.916)。
- 外部测试队列AUC为0.788(95%CI 0.633-0.944)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the predictive power of 2-[18F]FDG PET/CT-derived radiomic signature in human epidermal growth factor receptor 2 (HER2) status determination for primary breast cancer (BC) with equivocal immunohistochemistry (IHC) results for HER2.
METHODS: A total of 154 primary BC with equivocal IHC results for HER2 were retrospectively enrolled in the study. First, the following five conventional PET parameters (SUVmax, SUVmean, SUVpeak, MTV, TLG) were measured and compared between HER2-positive and HER2-negative cohorts. After quantitative radiomic features extraction and reduction, the least absolute shrinkage and selection operator (LASSO) algorithm was used to establish a radiomic signature model. Then, the area under the curve (AUCs) after a receiver operator characteristic (ROC) analysis, accuracy, sensitivity and specificity were calculated and used as the main outcomes. Finally, a total of 37 BC patients from an external institution were included to perform an external validation.
RESULTS: All the five conventional PET parameters were unable to discriminate between HER2-positive and HER2-negative cohorts for BC (P = 0.104-0.544). Whereas, the developed radiomic signature model was potentially predictive of HER2 status with an of AUC 0.887 (95% confidence interval [CI], 0.824-0.950) in the training cohort and 0.766 (95% CI, 0.616-0.916) in the validation cohort, respectively. For external validation, the AUC for the external test cohort was 0.788 (95% CI, 0.633-0.944).
CONCLUSIONS: Radiomic signature based on 2-[18F]FDG PET/CT images was capable of non-invasively predicting the HER2 status with a comparable ability to FISH assay, especially for those with equivocal IHC results for HER2.
引用
- Liu J, Zhang Z, Bian H, et al. Predictive value of radiomic signature based on 2-[18F]FDG PET/CT in HER2 status determination for primary breast cancer with equivocal IHC results. Eur J Radiol. 2023. PMID: 37598640. doi:10.1016/j.ejrad.2023.111050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。